Literature DB >> 3987788

Pharmacokinetics and Pharmacodynamics of procyclidine in man.

P D Whiteman, A S Fowle, M J Hamilton, A W Peck, A Bye, K Dean, A Webster.   

Abstract

The pharmacokinetics and pharmacodynamics of procyclidine (10 mg) after oral and intravenous administration were studied in six healthy volunteers. Treatment order was randomised and the study was placebo-controlled and conducted blind. After oral dosing the mean peak plasma concentration was 116 ng/ml and mean bioavailability was 75%. After both oral and intravenous dosing the mean values for the volume of distribution, total body clearance and plasma elimination half-life of procyclidine were in the order of 1 l/kg, 68 ml/min and 12 h respectively. Autonomic effects were maximal within 0.5 h of intravenous administration and at about 1-2 h after oral dosing. Significant effects on pupil diameter, visual near point, salivary secretion and heart rate occurred after intravenous treatment and similar but less marked effects occurred after the oral dose. Significant autonomic effects were still detectable 12 h after both forms of treatment.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3987788     DOI: 10.1007/bf00635711

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

1.  KEMADRIN IN THE TREATMENT OF PARKINSONISM: A DOUBLE BLIND AND ONE-YEAR FOLLOW-UP STUDY.

Authors:  R R STRANG
Journal:  Curr Med Drugs       Date:  1965-04

2.  Cholinergic activity of atropine.

Authors:  A ASHFORD; G B PENN; J W ROSS
Journal:  Nature       Date:  1962-03-17       Impact factor: 49.962

3.  CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates.

Authors:  A J Sedman; J G Wagner
Journal:  J Pharm Sci       Date:  1976-07       Impact factor: 3.534

4.  The parasympathomimetic activity of atropine and atropine methylbromide.

Authors:  C A Kottmeier; J S Gravenstein
Journal:  Anesthesiology       Date:  1968 Nov-Dec       Impact factor: 7.892

5.  Analysis of procyclidine in human plasma and urine by gas-liquid chromatography.

Authors:  K Dean; D Land; A Bye
Journal:  J Chromatogr       Date:  1980-12-12

6.  A comparison of piribedil, procyclidine and placebo in the control of phenothiazine-induced parkinsonism.

Authors:  R H Mindham; P Lamb; R Bradley
Journal:  Br J Psychiatry       Date:  1977-06       Impact factor: 9.319

7.  [Prophylaxis and therapy of a drug-related Parkinson syndrome with procyclidine hydrochloride (Kemadrin)].

Authors:  H GROSS; E LANGNER
Journal:  Wien Klin Wochenschr       Date:  1962-08-31       Impact factor: 1.704

  7 in total
  5 in total

Review 1.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

Review 2.  Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Authors:  Dirk Deleu; Margaret G Northway; Yolande Hanssens
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 3.  Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation.

Authors:  Chantal Schlatter; Sabin S Egger; Lydia Tchambaz; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 4.  Pharmacokinetic optimisation in the treatment of Parkinson's disease.

Authors:  M Contin; R Riva; F Albani; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

Review 5.  Exosomes in Parkinson: Revisiting Their Pathologic Role and Potential Applications.

Authors:  Yassamine Ouerdane; Mohamed Y Hassaballah; Abdalrazeq Nagah; Tarek M Ibrahim; Hosny A H Mohamed; Areej El-Baz; Mohamed S Attia
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.